An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Inclusion Criteria: * At least one eye must have EITHER a positive adenovirus test (using the Adeno Detector™ for Adenoviral Conjunctivitis, Rapid Pathogen Screening, Inc.) OR a positive clinical diagnosis assessed by the Adenoviral Clinical Diagnostic Checklist. * Onset and development of ocular symptoms and/or signs of conjunctivitis ≤ 7 days prior to enrollment (Day 1) in either eye. * Able to understand and sign an informed consent form that has been approved by an Institutional Review Board/ Independent Ethics Committee (IRB/IEC). * Must agree to comply with the visit schedule and other requirements of the study. * Females who are not pregnant and are not lactating. All females of childbearing potential (those who are not pre-menarcheal, not postmenopausal or surgically sterile) may participate only if they have a negative urine pregnancy test prior to randomization, and if they agree to use adequate birth control methods to prevent pregnancy throughout the study. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Sub-epithelial infiltrates at the Day 1 visit in either eye. * Corneal opacity or any corneal abnormality at the Day 1 visit in either eye. * Contact lens wear during the course of the study. Participants requiring correction must have spectacles with appropriate correction. * Only one sighted eye or vision in either eye not correctable to 0.6 or better logMAR (using ETDRS chart) at the Day 1 visit. * Abnormal findings in the poster…